TY - JOUR
T1 - Two young stroke patients associated with regular intravenous immunoglobulin (IVIg) therapy
AU - Nakano, Yumiko
AU - Hayashi, Takeshi
AU - Deguchi, Kentaro
AU - Sato, Kota
AU - Hishikawa, Nozomi
AU - Yamashita, Toru
AU - Ohta, Yasuyuki
AU - Takao, Yoshiki
AU - Morio, Tomohiro
AU - Abe, Koji
N1 - Funding Information:
This work was partly supported by Grant-in-Aid for Scientific Research (B) 25293202 , (C) 15K09316 and Challenging Research 15K15527 and Young Research 15K21181 , and by Grants-in-Aid from the Research Committees (Mizusawa H, Nakashima K, Nishizawa M, Sasaki H, and Aoki M) from the Ministry of Health, Labour and Welfare, Japan .
Publisher Copyright:
© 2015 Elsevier B.V.
Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.
PY - 2016/2/15
Y1 - 2016/2/15
N2 - We recently experienced 2 young adult patients who developed ischemic stroke after regular intravenous immunoglobulin (IVIg) therapy for agammaglobulinemia with diagnosis of common variable immunodeficiency (CVID) in their childhood. Patient 1 was 26-year-old woman, who developed Wallenberg's syndrome 6 days after the last IVIg therapy, but had no further stroke recurrence with cilostazol later. Patient 2 was 37-year-old man, who developed recurrent cerebral infarction in the territory of bilateral lenticulostriate branches like branch atheromatous disease (BAD) several days after the IVIg therapy. However, he had no further stroke recurrence after bone marrow transplantation (BMT) therapy for his lymphoproliferative disorder. It was suggested that IVIg therapy was associated to these different types of ischemic stroke in our 2 young adult patients with minimal vascular risk factors. Although IVIg therapy is widely used as a relatively safe medication for immunodeficiency disorders or autoimmune diseases, we need to pay more attention to stroke occurrence with regular IVIg therapy.
AB - We recently experienced 2 young adult patients who developed ischemic stroke after regular intravenous immunoglobulin (IVIg) therapy for agammaglobulinemia with diagnosis of common variable immunodeficiency (CVID) in their childhood. Patient 1 was 26-year-old woman, who developed Wallenberg's syndrome 6 days after the last IVIg therapy, but had no further stroke recurrence with cilostazol later. Patient 2 was 37-year-old man, who developed recurrent cerebral infarction in the territory of bilateral lenticulostriate branches like branch atheromatous disease (BAD) several days after the IVIg therapy. However, he had no further stroke recurrence after bone marrow transplantation (BMT) therapy for his lymphoproliferative disorder. It was suggested that IVIg therapy was associated to these different types of ischemic stroke in our 2 young adult patients with minimal vascular risk factors. Although IVIg therapy is widely used as a relatively safe medication for immunodeficiency disorders or autoimmune diseases, we need to pay more attention to stroke occurrence with regular IVIg therapy.
KW - Agammaglobulinemia
KW - Intravenous immunoglobulin
KW - Stroke
KW - Thrombotic complication
UR - http://www.scopus.com/inward/record.url?scp=84958986553&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84958986553&partnerID=8YFLogxK
U2 - 10.1016/j.jns.2015.12.001
DO - 10.1016/j.jns.2015.12.001
M3 - Article
C2 - 26810508
AN - SCOPUS:84958986553
SN - 0022-510X
VL - 361
SP - 9
EP - 12
JO - Journal of the Neurological Sciences
JF - Journal of the Neurological Sciences
ER -